en · de · es · pt
tb-500-notes.peptides6088.com › Wiki › Thymosin Beta-4 Fragment Overview — What the Evidence Shows

Thymosin Beta-4 Fragment Overview — What the Evidence Shows

By Editorial Desk · published 2025-08-11 · last reviewed 2025-09-11 · Wiki

A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Handling, Stability and Analytical Detection

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Thymosin Beta-4 Fragment Identity

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

Related pages on this site

Identification and Molecular Background

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Research Framing and Evidence Base

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Identity and Research Background

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Supporting material

While the chain has grown nationwide, both of its two outlets in North Queensland closed in November 2022, which were previously locations in Cairns and Townsville. In April 2025, Taco Bell owner Collins Foods announced to exit the Australian operations, with the prospect of finding a buyer in 12 months or else winding up the business. In March 2026, just weeks from the deadline, Collins Foods successfully transferred the operations to Restaurant Brands, another partner in the area. 6 stores will close in Queensland and 1 in Victoria, leaving 20 in the deal but saving the company from demise and a more exorbitant closure.

== Clinical trials == Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination. The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.

== Personal life == Kiggans is a lifelong Roman Catholic. She has been married since 1999 to Steve Kiggans, a retired Navy F-18 pilot. They have four children. Kiggans' father is also a veteran, serving in the Vietnam War as an Army Green Beret.

=== Titles and styles === 9 May 1892 – 21 October 1911: Her Royal Highness Princess Zita of Parma 21 October 1911 – 28 June 1914: Her Imperial and Royal Highness Archduchess Zita, Archduchess Karl of Austria, Princess of Parma 28 June 1914 – 21 November 1916: Her Imperial and Royal Highness The Archduchess of Austria-Este 21 November 1916 – 3 April 1919: Her Imperial and Royal Apostolic Majesty The Empress of Austria, Apostolic Queen of Hungary and Croatia, Slavonia and Dalmatia

== Other uses == Gabriel Richard High School, a private high school in Michigan Golden Retriever, a dog breed Grain (unit) (gr), an amount of mass Gwoyeu Romatzyh, a system of romanization for Chinese

Sources: en.wikipedia.org

Supporting material

Cocaine overdose may cause seizures, abnormally high body temperature and a marked elevation of blood pressure, which can be life-threatening, abnormal heart rhythms, and death. Anxiety, paranoia, and restlessness can also occur, especially during the comedown. With excessive dosage, tremors, convulsions, and increased body temperature are observed.

In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials. In addition to its pharmaceutical manufacturing activities, Eurogentec became a service company for the biotechnical research industry and university laboratories. In 1999, Eurogentec acquired Oswel Research Product Ltd. a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA). In 2002, Eurogentec acquired Wita Proteomics, a company specialized in proteomics services, based in Berlin (Germany). A few months later, Eurogentec installed its US office in San Diego for the production of oligonucleotides (EGT NA).

==== Metabolism ==== Gabapentin, pregabalin, Baclofen and phenibut all undergo little or no metabolism. Conversely, gabapentin enacarbil, which acts as a prodrug of gabapentin, must undergo enzymatic hydrolysis to become active. This is done via non-specific esterases in the intestines and to a lesser extent in the liver.

Stickland fermentation or The Stickland Reaction is the name for a chemical reaction that involves the coupled oxidation and reduction of amino acids to organic acids. The electron donor amino acid is oxidised to a volatile carboxylic acid one carbon atom shorter than the original amino acid. For example, alanine with a three carbon chain is converted to acetate with two carbons. The electron acceptor amino acid is reduced to a volatile carboxylic acid the same length as the original amino acid. For example, glycine with two carbons is converted to acetate. In this way, amino acid fermenting microbes can avoid using hydrogen ions as electron acceptors to produce hydrogen gas. Amino acids can be Stickland acceptors, Stickland donors, or act as both donor and acceptor. Only histidine cannot be fermented by Stickland reactions, and is oxidised. With a typical amino acid mix, there is a 10% shortfall in Stickland acceptors, which results in hydrogen production. Under very low hydrogen partial pressures, increased uncoupled anaerobic oxidation has also been observed. It occurs in proteolytic clostridia such as: C. perfringens, Clostridioides difficile, C. sporogenes, and C. botulinum. Additionally, sarcosine and betaine can act as electron acceptors.

Sources: en.wikipedia.org

Supporting material

Type 1: This is a thin and filamentous juncturae tendinum. Its shape can either be square, rhomboidal or triangular. Type 2: This type is more tendinous and thicker than type 1 juncturae, and it is also located more distal than the type 1. Type 3: Type 3 juncturae refers to the slips from the extensor digitorum communis. Type 3 juncture is further divided into subtype 3r and 3y according to its shape, with the subtype 3r being more oblique than the 3y.

=== Drug delivery === The synthesis, characterization, and drug-related studies of low toxicity, biocompatible MOFs has shown that they have potential for medical applications. Many groups have synthesized various low toxicity MOFs and have studied their uses in loading and releasing various therapeutic drugs for potential medical applications. A variety of methods exist for inducing drug release, such as pH-response, magnetic-response, ion-response, temperature-response, and pressure response. In 2010, Smaldone et al., an international research group, synthesized a biocompatible MOF termed CD-MOF-1 from cheap edible natural products. CD-MOF-1 consists of repeating base units of 6 γ-cyclodextrin rings bound together by potassium ions. γ-cyclodextrin (γ-CD) is a symmetrical cyclic oligosaccharide that is mass-produced enzymatically from starch and consists of eight asymmetric α-1,4-linked D-glucopyranosyl residues. The molecular structure of these glucose derivatives, which approximates a truncated cone, bucket, or torus, generates a hydrophilic exterior surface and a nonpolar interior cavity. Cyclodextrins can interact with appropriately sized drug molecules to yield an inclusion complex. Smaldone's group proposed a cheap and simple synthesis of the CD-MOF-1 from natural products. They dissolved sugar (γ-cyclodextrin) and an alkali salt (KOH, KCl, potassium benzoate) in distilled bottled water and allowed 190 proof grain alcohol (Everclear) to vapor diffuse into the solution for a week.

He explained the importance of O'Higgins and his horse walking over the corpse of a dead enemy tyrant's soldier. The Cuban Army General Staff Band played El Mambi and La Bayamesa. The delegation from the Dominican Republic reminded the room that Máximo Gómez had been born in their country, and had died in Cuba. After a prayer to the Great Architect of the Universe, the Conference conducted its normal business.

Many biologics, skin substitutes, biomembranes and scaffolds have been developed to facilitate wound healing through various mechanisms. Other recent developments has been the renewed focus on the prominent patient concern of pain. Burn patients and others affected by severe wounds often report pain as the dominant negative impact of the wounds on their lives. Clinical management of the pain associated with chronic wounds has been an emergency wound treatment priority and is now viewed as an integral part of treatment.

== Achievements == Pultronics has contributed to the design flow of integrated circuits. Through the development of TED, an EDA thermal analysis tool of ICs, Pultronics provided an additional layer of verification to integrated circuit design. What makes TED different from other similar tools is that the thermal analysis is based on the physical topology of the IC instead of its schematic entry. Pultronics has also contributed to the testing of integrated circuits with the development of independent modules that could be placed directly on the IC. Such modules typically provide valuable information on the performance of the IC without resorting to complex measurement setups. Traditional methods of IC testing can require measurement equipment which are costly (>10-100k$) and can also distort the measured information.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

How should lyophilised peptide powder be stored?

Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.

Network